The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals
University Hospital, Gentofte, Copenhagen
10 participants
Jan 1, 2024
INTERVENTIONAL
Conditions
Summary
The study is a randomised, double-blinded, placebo-controlled, crossover study enrolling 10 healthy male participants. Each participant will undergo four separate study days in randomised order. Each study day encompasses a continous 90-minute i.v. infusion with either placebo, glucose-dependent insulinotropic polypeptide (GIP), alanine or GIP + alanine. The primary objective of the study is to find out whether intravenous administration of the naturally occuring gut hormone GIP and the amino acid alanine, separately and combined, results in additive or synergistic glucagonotropic effects during euglycaemic conditions in healthy participants. Secondary objectives are to disclose the effect of the abovementioned interventions on insulin secretion and circulating levels of total and individual amino acids.
Eligibility
Inclusion Criteria4
- Caucasian ethnicity
- Body mass index (BMI) 20-27 kg/m\^2
- Glycated haemoglobin (HbA1c) ≤ 42 mmol/mol
- Informed and written consent
Exclusion Criteria6
- Late microvascular complications except mild nonproliferative retinopathy
- Liver disease (alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) > 2 times normal values) or history of hepatobiliary disorder
- Treatment with any glucose-lowering drugs
- Active or recent (within 5 years) malignant disease
- Active tobacco smoking/use
- Any condition considered incompatible with participation by the investigators.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous saline during experimental days.
Intravenous GIP administration during experimental days.
Intravenous alanine administration during experimental days.
Intravenous administration of GIP and alanine during experimental days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06419686